8.75

0.23% -0.02

Pre-market: 8.27 -0.48 -5.49%

Avadel Pharmaceuticals Plc (AVDL)

Overview News Price History Option Chain Financials Why AVDL Down? Discussions Forecast

Avadel Pharmaceuticals Plc stock is traded at $8.75, with a volume of 1.17M. It is down -0.23% in the last 24 hours and up +9.24% over the past month. Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

Previous Close:

$8.77

Open:

$8.77

24h Volume:

1.17M

Relative Volume:

1.03

Market Cap:

$769.17M

Revenue:

$47.56M

Net Income/Loss:

$-156.83M

P/E Ratio:

-4.7814

EPS:

-1.83

Net Cash Flow:

$-127.98M

1W Performance:

+9.92%

1M Performance:

+9.24%

6M Performance:

-31.64%

1Y Performance:

-50.87%

1-Day Range:

$8.625

$8.82

1-Week Range:

$7.87

$8.82

52-Week Range:

$6.38

$19.09

Avadel Pharmaceuticals Plc Stock (AVDL) Company Profile

Name

Avadel Pharmaceuticals Plc

Sector

Healthcare (1153)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

636-449-1830

Address

BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, DUBLIN

Employee

188

Twitter

@AvadelPharma

Next Earnings Date

2025-03-03

Latest SEC Filings

AVDL's Discussions on Twitter

Compare AVDL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVDL Avadel Pharmaceuticals Plc	8.75	769.17M	47.56M	-156.83M	-127.98M	-1.83
ZTS Zoetis Inc	153.57	65.50B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.16	46.99B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.23	45.96B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	15.02	15.27B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	297.04	12.77B	2.76B	1.11B	898.10M	22.77

Avadel Pharmaceuticals Plc Stock (AVDL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Deutsche Bank	Buy
Jun-12-24	Initiated	Rodman & Renshaw	Buy
Mar-05-24	Reiterated	H.C. Wainwright	Buy
Mar-05-24	Reiterated	Needham	Buy
Mar-05-24	Reiterated	Oppenheimer	Outperform
Feb-06-24	Initiated	UBS	Buy
Nov-30-22	Upgrade	Jefferies	Hold → Buy
Aug-10-22	Downgrade	Jefferies	Buy → Hold
Jul-28-22	Resumed	Craig Hallum	Buy
May-26-22	Downgrade	Stifel	Buy → Hold
Sep-23-21	Initiated	Needham	Buy
Jul-31-20	Initiated	Oppenheimer	Outperform
Jul-21-20	Initiated	SVB Leerink	Outperform
Jun-30-20	Initiated	H.C. Wainwright	Buy
Apr-03-20	Initiated	Jefferies	Buy
Mar-12-20	Initiated	Stifel	Buy
Feb-26-20	Initiated	Piper Sandler	Overweight
Jan-30-20	Initiated	Craig Hallum	Buy
Jun-14-19	Upgrade	Ladenburg Thalmann	Neutral → Buy
Feb-08-19	Downgrade	Ladenburg Thalmann	Buy → Neutral

View All

Avadel Pharmaceuticals Plc Stock (AVDL) Latest News

Apr 28, 2025

UBS Adjusts Avadel Pharmaceuticals Price Target to $12 From $14, Maintains Buy Rating - marketscreener.com

Apr 28, 2025

Apr 27, 2025

LPL Financial LLC Purchases 10,072 Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World

Apr 27, 2025

JPMorgan Chase & Co. Has $1.17 Million Position in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World

Apr 27, 2025

Apr 25, 2025